FLAVONE ACETIC ACID ANALOGS AND METHODS OF USE THEREOF
    5.
    发明申请
    FLAVONE ACETIC ACID ANALOGS AND METHODS OF USE THEREOF 审中-公开
    FLAVONE ACE酸类似物及其使用方法

    公开(公告)号:WO2004075858A2

    公开(公告)日:2004-09-10

    申请号:PCT/US2004/005826

    申请日:2004-02-24

    IPC分类号: A61K

    CPC分类号: C07D215/233

    摘要: Compounds are described having a structure according to Formula (I) or Formula (II), wherein: X is selected from the group consisting of O, NH, and S; Y is selected from the group consisting of O and S; m is from 1 to 3; n is from 1 to 5; R 1 and R 3 are each independently selected from the group consisting of H, hydroxy, lower alkyl, lower alkoxy, halo, amino, aminoalkyl, nitro, heteroaryl, -OC(=O)R 6 , -O(C=O)OR 6 ; and -O(C=O)N(R 6 ) 2 ; and R 2 is side chain such as an acetic acid side chain, where p is O to 4, R 5 is hydroxy, alkoxy or amino, and R 6 is H or lower alkyl, or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of cancer.

    摘要翻译: 描述具有根据式(I)或式(II)的结构的化合物,其中:X选自O,NH和S; Y选自O和S; m为1〜3; n为1〜5; R 1和R 3各自独立地选自H,羟基,低级烷基,低级烷氧基,卤素,氨基,氨基烷基,硝基,杂芳基,-OC(= O)R 6,-O(C = O)OR 6; 和-O(C = O)N(R 6)2; R2是侧链如乙酸侧链,其中p为0至4,R5为羟基,烷氧基或氨基,R6为H或低级烷基或其药学上可接受的盐。 该化合物可用于治疗癌症。

    ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF
    10.
    发明申请
    ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF 审中-公开
    抗增生化合物,组合物及其使用方法

    公开(公告)号:WO2007002912A3

    公开(公告)日:2007-06-28

    申请号:PCT/US2006025726

    申请日:2006-06-29

    CPC分类号: C07F9/65616 Y02P20/55

    摘要: Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV, wherein: Y 1A and Y 1B are independently Y 1 ; R X1 is R X ; R X2 is alkenyl of 2 to 18 carbon atoms or alkynyl of 2 to 18 carbon atoms; Y 1 is = O, -O(R X ), =S, -N(R X ), -N(O)(R X ), -N(OR X ), -N(O)(OR X ), or -N(N(R X )(R X )); R X is independently R 1 , R 2 , R 4 , W 3 , or a protecting group; R 1 is independently -H or alkyl of 1 to 18 carbon atoms; R 2 is independently R 3 or R 4 wherein each R 4 is independently substituted with 0 to 3 R 3 groups or taken together at a carbon atom, two R 2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R 3 groups; R 3 is R 3a , R 3b , R 3c or R 3d , provided that when R 3 is bound to a heteroatom, then R 3 is R 3c or R 3d ; R 3a is -H, -F, -Cl, -Br, -I, -CF 3 , -CN, N 3 , -NO 2 or -OR 4 ; R 3b is = O, -O(R 4 ), =S, -N(R 4 ), -N(O)(R 4 ), -N(OR 4 ), -N(O)(OR 4 ), or -N(N(R 4 )(R 4 )); 3c is -R 4 , -N(R 4 )(R 4 ), -SR 4 , -S(O)R 4 , -S(O) 2 R 4 , -S(O)(OR 4 ), -S(O) 2 (OR 4 ), -OC(R 3b )R 4 , -OC(R 3b )OR 4 , -OC(R 3b )(N(R 4 )(R 4 )), -SC(R 3b )R 4 , -SC(R 3b )OR 4 , -SC(R 3b )(N(R 4 )(R 4 )), -N(R 4 )C(R 3b )R 4 , -N(R 4 )C(R 3b )OR 4 , -N(R 4 )C(R 3b )(N(R 4 )(R 4 )), W 3 or -R 5 W 3 ; R 3d is -C(R 3b )R 4 , -C(R 3b )OR 4 , -C(R 3b )W 3 , -C(R 3b )OW 3 or -C(R 3b )(N(R 4 )(R 4 )); R 4 is -H, or an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms; R 5 is alkylene of 1 to 18 carbon atoms, alkenylene of 2 to 18 carbon atoms, or alkynylene of 2 to 18 carbon atoms; W 3 is W 4 or W 5 ; W 4 is R 6 , -C(R 3b )R 6 , -C(R 3b )W 5 , -SO M2 R 6 , or -SO M2 W 5 , wherein R 6 is R 4 wherein each R 4 is substituted with O to 3 R 3 groups; W 5 is carbocycle or heterocycle wherein W 5 is independently substituted with O to 3 R 2 groups; and M2 is 0, 1 or 2; or pharmaceutically acceptable salts thereof.

    摘要翻译: 描述了式I的化合物和组合物,其可用作抗增殖剂,特别是抗HPV,其中:Y 1A和Y 1B独立地为Y, 1 ; R X1是R X; R 2 X 2是2至18个碳原子的链烯基或2至18个碳原子的炔基; Y 1是= O,-O(R X),= S,-N(R X)X - , - N(O)( N(O,X),-N(O)(OR X)或-N(N(R' SUP> X )(R X )); R X独立地为R 1,R 2,R 4,W 3, ,或保护基团; R 1独立地是-H或1至18个碳原子的烷基; R 2独立地是R 3或R 4,其中每个R 4独立地被0至3个R 3取代, SUP> 3个或3个碳原子一起取代,2个R 2基团形成3〜8个碳环,该环可以被0〜3个R 3 组 R 3是R 3a,R 3b,R 3c或R i,R 3, 条件是当R 3与杂原子结合时,R 3是R 3c或R 3d; R 3a是-H,-F,-Cl,-Br,-I,-CF 3,-CN,N 3 - , - NO 2或-OR 4; R 3是= O,-O(R 4),= S,-N(R 4), - N(O)( (OR 4),-N(OR 4), - N(O)(OR 4)或-N(N(R' SUP> 4 )(R 4 )); (S 4),-S(R 4),-SR 4,-S(R 4) 4,-S(O)R 4,-S(O)2 R 4,-S(O)( 或(S)4),-S(O)2(OR 4),-OC(R 3b)R -OC(R 3b)或OR 4,-OC(R 3b)(N(R 3) (R 4)),-SC(R 3b)R 4,-SC(R SUP) (R 3)(R 4)(R 4)(R 4) /(S)S),-N(R 4)S(R 3b)R 4,-N(R 4) C(R 3b)或者4,-N(R 4)C(R 3) )(N(R 4)(R 4)),W 3或-R 5 W > 3 ; R 3 d 3是-C(R 3b)R 4,-C(R 3b)或 - -C(R 3b)W 3,-C(R 3b)OW 3 O, >或-C(R 3b)(N(R 4))(R 4)); R 4是-H或1至18个碳原子的烷基,2至18个碳原子的烯基或2至18个碳原子的炔基; R 5是1至18个碳原子的亚烷基,2至18个碳原子的亚烯基或2至18个碳原子的亚炔基; W 3或W 5是W 4或W 5; R 4是R 6,-C(R 3b)R 6,-C(R'), 或3个或更多个,其中,R 1,R 2,R 3,R 5, 其中R 6是R 4,其中每个R 4被0至3个R 3取代, / SUP>组 W 5是碳环或杂环,其中W 5独立地被O至3个R 2基团取代; M2为0,1或2; 或其药学上可接受的盐。